Stock SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-06-04 pm EDT 		5-day change 1st Jan Change
1.615 USD -0.92% Intraday chart for Sonnet BioTherapeutics Holdings, Inc. -0.31% -7.18%
May. 28 Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting CI
May. 22 Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
GL
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
AQ
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting
CI
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
AQ
Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives
CI
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
AQ
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K
PU
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target
CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
NE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting
AQ
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
MT
Top Premarket Gainers
MT
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080
CI
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
AQ
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating
MT
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
AQ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SONN Stock
  4. News Sonnet BioTherapeutics Holdings, Inc.